Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telitacicept for ANCA-associated nephritis
NCT06656962Phase 2Active, not recruiting
- Sponsor
- Renmin Hospital of Wuhan University
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in ANCA-associated glomerulonephritis (ANCA-GN), sponsored by Renmin Hospital of Wuhan University. Started Oct 2024; status: active, not recruiting.
02
Drugs
telitacicept
03
Conditions
ANCA-associated glomerulonephritis (ANCA-GN)
Beyond the preview
Go deeper on NCT06656962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06656962.